NMPA published seven guidelines on post-market surveillance for medical device manufacturers in April 2026. These documents establish a mandatory, risk‑based vigilance system under the Medical Device Vigilance Quality Management Standards (Trial), supported by detailed implementation guides for trend reporting, periodic safety update reports (PSURs), risk evaluation, vigilance planning, and inspection checkpoints. This article provides an overview of the key requirements and highlights three critical topics – GMP & vigilance integration, PSUR preparation and legal representation – that foreign manufacturers must prioritize to ensure compliance.
For our recorded webinar on Post Market Surveillance, click HERE
For QMS & PMS questions about medical devices, IVD, and CDx, click HERE
For more information on PSUR, click HERE
The seven documents are listed below:
- Medical Device Vigilance Quality Management Standards (Trial)
- Guideline for Writing Medical Device Trend Reports (Trial)
- Guideline for Product Adverse Event Risk Evaluation for Medical Device Registrants (2026 Revision)
- Guideline for Writing Medical Device Periodic Safety Update Reports (Trial)
- Guideline for Review of Medical Device Periodic Risk Evaluation Reports (Trial)
- Guideline for Writing Medical Device Vigilance Plans (Trial)
- Medical Device Vigilance Inspection Checklist (Trial)
Together, they mandate a vigilance system covering data collection, risk analysis, reporting, control measures, and regulatory communication.
Core Elements of the New Vigilance Framework
1. Vigilance System and Documentation
Registrants must establish a vigilance system implemented in their quality management system. Key components include:
– A dedicated vigilance organization with clear roles.
– Adequate personnel, equipment, and resources.
– Written SOPs for data collection, reporting, and evaluation.
– An effective channel for collecting vigilance information (user feedback, complaints, literature).
– Risk identification and control mechanisms.
– Traceable records with defined retention periods.
A statutory Vigilance Leadership Team must be formed, headed by the legal representative or principal responsible person, including the vigilance officer and relevant department heads. For foreign manufacturers, the Chinese legal agent must be a member of this team. A designated Vigilance Officer – a manager with appropriate experience – is responsible for data collection, risk assessment, document approval, regulatory communication, and ensuring overall compliance.
2. Vigilance Plan
Each product requires a written vigilance plan that includes:
– Product scope and specific vigilance objectives (e.g., monitoring risk trends, updating known risks).
– Data sources (active monitoring, literature, complaints).
– Risk analysis methodology (control charts, Pareto, histograms, etc.).
– Risk acceptability criteria (based on ISO 14971).
– Post‑market safety evaluation triggers.
– Schedule for plan review and updates.
The plan must be reviewed periodically and updated when necessary, with version control in place.
3. Trend Reports
Registrants must establish a trend analysis procedure and analyze vigilance data weekly, monthly, or quarterly. If the frequency or severity of product problems or injuries exceeds a predefined threshold, an initial trend report must be submitted within 20 days. Follow‑up reports are required if the trend persists, and a final trend report is submitted once the trend is controlled. The guideline provides statistical methods (control charts, histograms, Pareto) and real‑world examples (e.g., a dialyzer manufacturer detecting complaint rates above control limits and taking immediate corrective action).
4. Periodic Safety Update Reports (PSURs)
For Class II and III devices, a PSUR must be submitted via the national adverse event monitoring system within 60 days after each full year of the initial registration cycle. For renewed registrations, the PSUR covers the entire registration period and must be kept on file for the next renewal application. Each PSUR must include:
– Product and global sales/usage data.
– Aggregated vigilance data with incidence rates (using IMDRF codes for product problems, injury terms, and root causes).
– Trend analysis results.
– Summary of risk control measures.
– Benefit‑risk conclusion.
PSURs must be continuous and complete – no data gaps are allowed.
5. Product Risk Evaluation
When an individual adverse event or aggregated analysis suggests an unacceptable risk, registrants must conduct a formal product risk evaluation. The investigation covers:
– Product and patient information, use conditions.
– Domestic and overseas adverse event data.
– Literature review.
– Production process and complaint history.
– If necessary, retesting of retained samples.
The final risk evaluation report (following a prescribed format) must be submitted to the provincial drug authority. Required risk controls (label changes, design modifications, recall, etc.) must be implemented and their effectiveness tracked.
6. PSUR Review and Inspection
The PSUR review guide sets clear criteria for acceptance or rejection. A PSUR will be returned for issues such as:
– Incorrect data coverage period (gaps or misaligned dates).
– Missing core sections (e.g., no trend analysis, no risk control summary).
– Inconsistent adverse event counts compared to the national system.
– Absence of required attachments (e.g., updated instructions for use).
This ensures uniform scrutiny across all provincial monitoring centers.
7. Vigilance Inspection Checklist
Inspectors will verify:
– Existence of the vigilance system and documented procedures.
– Formation and functioning of the vigilance leadership team and officer.
– Training records and competency of vigilance personnel.
– Execution of the vigilance plan.
– Collection of data from complaints, literature, and active monitoring.
– Performance of trend analysis and timely submission of trend reports.
– Submission of PSURs and risk evaluation reports.
– Implementation of risk controls and safety communications (e.g., letters to healthcare professionals).
– Post‑market safety evaluations for high‑risk products (innovative devices, high‑risk implants, life‑sustaining devices used outside healthcare facilities, high‑risk pediatric devices, and any product required by the NMPA).
Non‑compliance can lead to product suspension, recall, or even registration revocation. The entire framework is designed to ensure that manufacturers continuously monitor, identify, assess, and control risks throughout the product lifecycle.
GMP-Vigilance Integration
The seven NMPA vigilance documents must be integrated with the new Medical Device Production Quality Management Standards (GMP, effective 1 November 2026). Under the GMP, a compliant quality management system (QMS) must embed vigilance into routine production. It mandates an adverse event monitoring system, data analysis for product quality and feedback, and CAPA – directly supporting trend reports and PSURs. The GMP’s risk management requirements provide the foundation for vigilance plans and product risk evaluations. Change control and recall systems ensure safety signals trigger corrective actions. Complaint handling and product information notifications link directly to vigilance data collection and PSUR workflows. Electronic record and data integrity provisions support traceable safety data. In essence, the seven documents operationalize post‑market safety elements that the GMP mandates at a system level. GMP compliance is impossible without a functioning vigilance system producing trend reports, PSURs, risk evaluations, and documented risk controls – all integrated into the QMS.
PSUR Preparation Services
Given the technical complexity of PSURs – correct data aggregation over continuous 12‑month periods, mandatory use of IMDRF terminology, incidence rate calculations, statistical comparisons across reporting periods, and strict adherence to the review checklist – many manufacturers outsource PSUR preparation to specialized regulatory consultants.
Legal Agent Services for Overseas Manufacturers
Under Articles 2 and 9 of the Vigilance Quality Management Standards, overseas medical device registrants or filing parties must designate a legal agent in China – formally referred to as the “Importer’s Domestic Responsible Party”.
Legal agent will play a far more significant role than ever before. China Med Device, LLC is an NMPA certified legal agent. We can help you fulfill the pre and post market legal agent requirements without your needing to setup office in China. For more details on legal agent regulations, email us at info@ChinaMedDevice.com.
- Handle the registration or filing of imported medical devices;
- Monitor and report the adverse events in China, and feedback to foreign manufacturers and regulatory agencies; Assist regulatory agencies with quality inspection;
- Keep track with sales and distribution and ensure that products are traceable；
- Notify foreign manufacturers of any regulatory updates and technical requirements;
- Investigate and handle consumer complaints, and report to foreign manufacturers;
- Share liability with manufacturer on quality and service issues;
- Conduct yearly self-inspection for overseas manufacturers and legal agent itself;
- Assist manufacturers meet requirements for Conditional Approval;
- Responsible for Chinese IFU;
- Timely submit PSUR with full deliverables: multi‑certificate management, literature searches, required tables, and benefit‑risk conclusions.